Medical/Pharmaceuticals
Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting
SAN FRANCISCO and SUZHOU, China, Sept. 23, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmun...
2026-09-23 16:48
787
Caliway Announces Positive Phase 2 Results of CBL-514 in Dercum's Disease, Achieving Primary Endpoint with Statistically Significant and Sustained Pain Reduction
* Primary Endpoint Achieved in CBL-0202DD Phase 2 Trial—CBL-514 delivered statistically significant pain reduction across both FAS and PP populations compared with placebo. * Expansion Opportunity Beyond Dercum's Disease—Study findings support the potential development of CBL-514 for Lipedema...
2026-09-23 10:08
1011
GROWNSY Makes NANN Conference Debut, Partners with NANN and Pediatrician Dr. Molly O'Shea on NANNcast Episode Tackling Infant Nasal Congestion
The company exhibited for the first time at NANN's 42nd Annual Conference in West Palm Beach and will sponsor a NANNcast episode exploring why newborns are so vulnerable to nasal congestion — and what neonatal nurses and parents can do about it. NEW YORK, Sept. 22, 2026 /PRNewswire/ -- GROWNSY <...
2026-09-23 09:36
587
XtalPi AI Enables Seven-Month PCC Nomination for Viva-Thera's MPER-Targeting HIV-1 Program
* Viva-Thera makes its public debut with four modalities pursuing HIV prevention, treatment and cure, supported by XtalPi's platform capabilities. * Viva-Thera combines its first atomic-resolution MPER-TMD-CT structure with XtalPi's AI and automation platform to advance a small-molecule PCC. ...
2026-09-23 01:36
346
Tsingke Enables High-Throughput Validation of AI-Designed Proteins and Antibodies
BEIJING, Sept. 22, 2026 /PRNewswire/ -- Tsingke today announced an integrated high-throughput validation workflow designed to help researchers experimentally evaluate large libraries of AI-designed proteins and antibodies. Combining gene synthesis, parallel expression, high-throughput screening, ...
2026-09-22 22:22
345
NUH ENDOCRINOLOGY TEAM SHOWCASES END-TO-END CARE MODEL THAT PROTECTS HOSPITALISED PATIENTS WITH DIABETES MELLITUS (DM) ACROSS THEIR CARE JOURNEY
NUH's Inpatient DM management team highlights how safe prescribing is strengthened through proactive monitoring, rapid intervention and coordinated care transitions. SINGAPORE, Sept. 21, 2026 /PRNewswire/ -- Newer diabetes treatments are transforming care, helping patients not only manage their ...
2026-09-22 15:46
734
BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset
SUZHOU, China, Sept. 22, 2026 /PRNewswire/ -- Boomray Pharmaceuticals Co., Ltd. ("BoomRay"), a clinical-stage biotechnology company pioneering innovative radioligand therapies (RLTs) for precision oncology diagnostics and therapeutics, today announced that it has entered into an exclusive global ...
2026-09-22 12:00
1409
Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026
HONG KONG, Sept. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company")announced that nearly 30 clinical studies of its globally first-in-class bispecific antibodies will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress, taking place October 23–27 ...
2026-09-22 07:46
1461
The Next Chapter of B7-H3: From Systemic Disease to the Brain
Early Data for T-MAXIMUM's B7-H3 Allogeneic CAR-T in Brain Metastases Presented at WCLC 2026 BEIJING, Sept. 21, 2026 /PRNewswire/ -- As B7-H3 ADCs reshape the second-line treatment landscape for small cell lung cancer at WCLC, a more specific question comes into focus: systemic disease now has n...
2026-09-21 19:50
927
WuXi XDC Celebrates GMP Release of Singapore Site, Ushering in a New Era of Global Expansion
SINGAPORE, Sept. 21, 2026 /PRNewswire/ --WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today held a grand GMP release ceremony for its Singapore manufacturing sit...
2026-09-21 17:50
1754
Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia
SINGAPORE, Sept. 20, 2026 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST)today announced an expansion of its existing partnership with Incyte Biosciences International, an affiliate of Incyte (NASDAQ: INCY), to commercialise, distribute, and register ruxolitini...
2026-09-21 04:00
1957
Accro Bioscience Announces First Patient Dosed in Phase IIb Study of AC-101 in Moderate-to-Severe Ulcerative Colitis
NEW YORK and SUZHOU, China, Sept. 20, 2026 /PRNewswire/ -- Accro Bioscience Inc. (Accro Bio), a clinical-stage biotechnology company pioneering the development of novel therapeutics for immune mediated diseases, today announced the dosing of their first patient in the Phase IIb clinical trial of ...
2026-09-20 18:00
2554
NAVER D2SF Invests in AI-Driven Precision Medicine Company ImpriMed
* ImpriMed combines ex vivo functional testing with multimodal AI to support personalized cancer treatment decisions and drug development * The investment is part of ImpriMed's $10 million Series A2 bridge round as the company advances U.S. commercialization and expands into Asia * NAVER D2S...
2026-09-18 23:00
3172
Datasea's AI Agent Digital Marketing Services Enter Scaled Commercial Deployment, with Five Agreements Representing Potential Annualized Service Volume of Up to Approximately US$89.4 Million (RMB600 Million)
Five-customer AI agent services advance into actual delivery; CEO reiterates long-term confidence through a previously disclosed US$1.0 million Rule 10b5-1 share purchase plan BEIJING, Sept. 17, 2026 /PRNewswire/ -- Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) ("Datasea" or the "Company"),...
2026-09-17 21:10
4355
Dr. Alison Armour agrees to become Chief Medical Officer of Alpha Fusion, as Company Advances Integration of At-211 Businesses with Curadh MTR
— Combining Both Companies' Astatine At-211 Assets, Development Capabilities, and Supply Chains to Create a Global Targeted Alpha Therapy Company — TOKYO, Sept. 17, 2026 /PRNewswire/ -- Alpha Fusion Inc. ("Alpha Fusion"), a clinical-stage company with an advanced At-211 drug platform, and Curadh ...
2026-09-17 19:00
2070
111 Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the Company
SHANGHAI, Sept. 17, 2026 /PRNewswire/ -- 111 Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, today announced that its Board of Directors (the "Board") has received an unsolicited preliminary non-binding proposal letter (the "Proposal") dat...
2026-09-17 16:25
5381
WuXi XDC Out-Licenses WuXiTecan-2 Payload-Linker Technology Platform to Ona Therapeutics to Advance Novel ADC Research and Development
SHANGHAI, Sept. 17, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced an out-licensing collab...
2026-09-17 16:09
2346
111, Inc. Announces Second Quarter 2026 Unaudited Financial Results
* Transition from An Asset-Heavy Business Model to An Asset-Light Business Model * Ongoing Investment and Adoption of AI Agents Making Workforce Streamlining Possible * Net Revenue of Promotional Products (1) Increased by 121% and Gross Profit Rose by 120% Year-over-Year * Total Marketpla...
2026-09-17 15:00
6166
Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate
HONG KONG, Sept. 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that AK158D1, its investigational next-generation bispecific antibody-drug conjugate (ADC) targeting EGFR and TROP2, has secured Phase I clinical trial clearance from the Center for Drug Evaluatio...
2026-09-17 14:34
1681
Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK Site
* Piramal Pharma Solutions is installing a ground-mounted solar power plant (4.3 MWp) at its integrated drug substance and drug product site in Morpeth, UK. * The new plant will provide renewable energy directly to the site through a behind-the-meter setup, supporting Piramal's commitment to re...
2026-09-16 22:28
3398
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 295 media titles]
2026-09-18 16:29CityUHK and University of Cambridge establish Centre for Advanced and Smart Manufacturing to shape Hong Kong's Industry 5.0 future
[Picked up by 289 media titles]
2026-09-22 18:37
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
01F Group Announces Investment in DANA, Indonesia's Leading Digital Financial Company, Reinforcing Long-Term Confidence in Asia's Fintech Opportunity
[Picked up by 273 media titles]
2026-09-21 08:00Tetra Pak and Soy Excellence Center Asia Host Regional Soy Food and Beverage Programme in Thailand
[Picked up by 268 media titles]
2026-09-18 11:51
Most Read
COSRX Brings Its 5 Peptide Lip Collection to Ulta Beauty Stores Offline
2026-09-18 22:00
10764
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
2026-09-17 13:09
9905
Ohmyhome Limited Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
2026-09-17 20:00
8098
American Savings Bank Jumps More Than 6% in Trading Debut: NYSE Content Update
2026-09-17 21:21
7700
